Spinal FusionTAPISNCT07218133
Trans-Auricular Stimulation for Postoperative Inflammation in Spine Surgery
A study testing Auricular vagus nerve stimulation in people with Spinal Fusion and Hyperglycemia, run by Alexander T. Yahanda at 1 site in United States.
Trial summary
This study is a randomized controlled trial that will evaluate the effect of non-invasive auricular vagal nerve stimulation on inflammatory markers, glycemic control, postoperative pain, and inflammation-related clinical outcomes after long-segment spinal fusion surgeries when compared to current accepted management. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Spinal Fusion, Hyperglycemia, Postoperative Pain Management
- What is being tested?
- Auricular vagus nerve stimulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 8 Oct 2025to Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Long-segment spinal fusions (defined as constructs spanning at least L2-pelvis for thoracolumbar fusions or C2-T2 for cervical fusions)
- Ability to undergo a reliable neurologic examination and pain assessments
Who cannot join
- Patients <18 years of age
- Shorter-segment spinal fusions than those described above
- Undergoing current active cancer therapy
- Undergoing treatment with immunosuppressive drugs
- Additional spinal surgery within past 6 months
- Sustained bradycardia or presence of pacemaker
- History of substance abuse
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Washington University School of Medicine
St Louis, Missouri, 63110
Alexander T Yahanda, MD, MPHS, 2604946828, ayahanda@wustl.edu
Eric C Leuthardt, MD
About this study
This study is a randomized controlled trial that will evaluate the effect of non-invasive auricular vagal nerve stimulation on inflammatory markers, glycemic control, postoperative pain, and inflammation-related clinical outcomes after long-segment spinal fusion surgeries when compared to current accepted management.
Read the detailed description
Long-segment spinal fusions are effective interventions to relieve pain, neurological compromise, or disability related to a variety of causes of advanced spinal degeneration or spinal deformity. Despite advancements in minimally invasive spine surgery, revision of prior instrumentation, correction of coronal or sagittal imbalance, bony decompression, and multilevel arthrodesis often must be performed via open surgery. While these procedures can produce excellent results with regards to postoperative alignment, neural decompression, and functional improvement, they are long and invasive cases requiring large incisions and extensive soft tissue dissection and osseous manipulation. As such, postoperative adverse events or complications are common (e.g., DVT/PE, wound healing problems, infection, nerve stretch injury, etc.). These patients almost universally experience significant postoperative pain, require postoperative rehabilitation, and are at high-risk for hospital readmissions. Moreover, the sterile trauma from long-segment spinal surgeries is a tremendous systemic inflammatory stimulus that yields downstream sequelae such as hyperglycemia, elevated inflammatory markers (e.g. cytokines), signs of microvascular ischemia, and other stress-related outcomes. Attempts to control this inflammation and reduce the adverse effects of these surgeries are lacking, particularly with respect to non-pharmacologic options.
Vagal nerve stimulation (VNS) is a promising emerging modality by which the body's systemic inflammatory response may be attenuated. Importantly, VNS may be successfully applied via noninvasive auricular stimulation. This technique has been trialed as non-pharmacologic pain control adjunct after multiple types of surgeries or painful medical events, but none as traumatic as long-segment spinal fusion. It also has been shown to yield substantial anti-inflammatory effects in numerous animal models. Furthermore, auricular VNS has been extensively studied at Washington University School of Medicine in multiple neurological conditions, including aneurysmal subarachnoid hemorrhage, acute ischemic stroke, and intraparenchymal hemorrhage. The use of noninvasive VNS devices has been shown to be an intervention that is safely administered and does not cause undue distress to patients. Given these promising aspects of VNS, Washington University's particular interest in this treatment modality, and the unmet postoperative care needs for long-segment spinal fusion patients, the investigators propose prospectively studying the effects of auricular VNS in a population of patients at Barnes-Jewish Hospital who have undergone long-segment fusion surgeries. The investigators hypothesize that perioperative VNS will mitigate the systemic inflammatory reaction in these patients as demonstrated by reduced inflammatory markers (both direct and indirect) and improved inflammatory-mediated clinical outcomes.
This study will be a randomized controlled trial assessing differences between accepted perioperative care plus auricular VNS (the intervention) as compared to accepted perioperative care plus a sham stimulus. The VNS device will be a noninvasive stimulator applied to the left ear to stimulate the auricular branch of the vagus nerve. All patients will be fitted with the device, and the sham stimulus will not receive the required therapeutic stimulation through the device. Patients will receive stimulation twice on the day of surgery followed by twice daily during the duration of their postoperative hospital admission. Relevant inflammatory cytokines, laboratory tests, pain scores, clinical outcomes, and imaging studies will be obtained for each patient. Post-hospital disposition, delayed adverse outcomes, and hospital readmissions will also be tracked after discharge.
- Conditions
- Spinal Fusion, Hyperglycemia, Postoperative Pain Management, Postoperative Care, Spine Disease, Neurologic Deficits
- Being tested
- Auricular vagus nerve stimulation, Sham Auricular Vagus nerve Stimulation
- Keywords
- spinal fusion, postoperative pain, glycemic control, inflammation, vagal nerve stimulation, postoperative complications, cytokine, spine surgery
- Medical subject headings
- Hyperglycemia, Spinal Diseases, Neurologic Manifestations, Nervous System Diseases, Inflammation, Pain, Postoperative, Postoperative Complications
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Auricular vagus nerve stimulationDevice
Transcutaneous auricular vagal nerve stimulation
Sham Auricular Vagus nerve StimulationDevice
Transcutaneous auricular vagal nerve stimulator applied without utilizing stimulating current.
| Study group | Role | What they receive |
|---|---|---|
| Auricular vagal nerve stimulation | Experimental | Participants will receive vagal nerve stimulation twice on the day of surgery (once preoperatively) and twice daily postoperatively for duration of hospitalization.
All patients will be fitted with the device via adhesive contacts to the left ear. Stimulation will occur for 20 minutes per session. The intervention will provide stimulation according to the following parameters: frequency 20 Hz, pulse width 250 µm, and fixed intensity of 0.5 milliampere. The amplitude of stimulation may be reduced if a patient complains of discomfort at the site of stimulation Receives: Device: Auricular vagus nerve stimulation |
| Sham vagal nerve stimulation | Sham comparator | Participants will have an auricular vagal nerve stimulator device applied in the same manner as the experimental arm, but they will not receive the actual stimulation. Receives: Device: Sham Auricular Vagus nerve Stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Inflammatory cytokine levels
The levels of 4 different inflammatory cytokines will be measured: interleukin-6 (IL-6), IL-1, IL-10, and tumor necrosis factor alpha (TNF-a) (all measured in pg/ml). Blood for these tests will be drawn preoperatively, postoperatively, on postop day 3, and postop day 6 (or time of discharge).
Measured: 5-10 days (depending on hospital admission length)
Secondary outcomes (13)
Pain scores
Patient pain levels will be assessed twice daily using the visual analogue scale (VAS), a validated pain reporting scale that uses a 100-millimeter horizontal line with anchors at "no pain" (0) and "worst possible pain" (100). Patients draw a line along this spectrum to signify their pain level. Higher distance along the spectrum in a left-to-right direction indicates higher pain.
Measured: 5-10 days (depending on hospital admission length)
blood glucose levels
Glucose measurements will be obtained multiple times daily via bedside point-of-care testing as well as through daily CMP labs (in mg/dL).
Measured: 5-10 days (depending on hospital admission length)
Postoperative adverse events/complications
Investigators will track the incidence of postoperative adverse events or complications, including temporary radiculopathy or nerve stretch injury, deep vein thrombosis (DVT), pulmonary embolism (PE), acute kidney injury (AKI), ileus, wound healing problems, hospital delirium, transfusion reactions, and infections. All patients will receive screening lower extremity doppler (LED) studies before surgery and at time of hospital discharge.
Measured: 5-10 days (depending on hospital admission length)
Secondary markers of inflammation
Daily laboratory studies that serve as surrogate markers for the body's degree of systemic inflammation will be obtained. This includes labs such as CRP, cortisol, creatinine, and troponin (all in mg/dL)
Measured: 5-10 days (depending on hospital admission length)
Post-hospitalization disposition
Investigators will track patients' post-hospitalization disposition (e.g. home versus inpatient rehabilitation).
Measured: 5-10 days (depending on hospital admission length)
Heart rate
Investigators will continuously monitor patients' heart rates to capture incidences of bradycardia that may be associated with the VNS intervention.
Measured: Time Frame: 5-10 days (depending on hospital admission length)
Opioid usage
Patients' daily opioid usage will be recorded while hospitalized. Usage will be converted to morphine milligram equivalents (MME).
Measured: 5-10 days (depending on hospital admission length)
Insulin requirements
Insulin requirements (units insulin) for patients during their hospital stay will be recorded.
Measured: 5-10 days (depending on hospital admission length)
Erythrocyte sedimentation rate (ESR)
Postoperative ESR will be measured daily (in mm/hr) to assess systemic inflammation.
Measured: 5-10 days (depending on hospital admission length)
D-dimer levels
D-dimer levels will be obtained postoperatively every other day (in microgram/mL)
Measured: 5-10 days (depending on hospital admission length)]
Hospital admission length
Length of patient hospital stay after surgery will be recorded.
Measured: 5-10 days (depending on hospital admission length)
Blood pressure
Tracking of blood pressure and temperature will allow investigators to evaluate the potential influence of VNS on blood pressure control for hypertensive patients and to determine if any hypotensive events are associated with the intervention.
Measured: 5-10 days (depending on hospital admission length)]
Readmission rates
The incidence of hospital readmission within 30 days and 60 days will be recorded (yes versus no readmissions).
Measured: 60 days postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2025
- Study start8 Oct 2025
- Primary completionJan 2027 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Spinal FusionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be assigned to either the vagal nerve stimulation arm or the sham stimulation arm.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Alexander T. Yahanda
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Alexander T. Yahanda, Washington University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07218133
- Sponsor's protocol ID
- 202407057SpineVNS
- Acronym
- TAPIS
- Status last verified
- Sep 2025
- First submitted
- 8 Oct 2025
- Last updated
- 18 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Trans-Auricular Stimulation for Postoperative Inflammation in Spine Surgery
- ClinicalTrials.gov ID
- NCT07218133
- Acronym / sponsor ID
- TAPIS / 202407057SpineVNS
- Conditions
- Spinal Fusion, Hyperglycemia, Postoperative Pain Management, Postoperative Care, Spine Disease, Neurologic Deficits
- Keywords
- spinal fusion, postoperative pain, glycemic control, inflammation, vagal nerve stimulation, postoperative complications, cytokine, spine surgery
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Alexander T. YahandaUniversity, hospital or other
- Study start
- 8 Oct 2025 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 20 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a randomized controlled trial that will evaluate the effect of non-invasive auricular vagal nerve stimulation on inflammatory markers, glycemic control, postoperative pain, and inflammation-related clinical outcomes after long-segment spinal fusion surgeries when compared to current accepted management.
Detailed description
Long-segment spinal fusions are effective interventions to relieve pain, neurological compromise, or disability related to a variety of causes of advanced spinal degeneration or spinal deformity. Despite advancements in minimally invasive spine surgery, revision of prior instrumentation, correction of coronal or sagittal imbalance, bony decompression, and multilevel arthrodesis often must be performed via open surgery. While these procedures can produce excellent results with regards to postoperative alignment, neural decompression, and functional improvement, they are long and invasive cases requiring large incisions and extensive soft tissue dissection and osseous manipulation. As such, postoperative adverse events or complications are common (e.g., DVT/PE, wound healing problems, infection, nerve stretch injury, etc.). These patients almost universally experience significant postoperative pain, require postoperative rehabilitation, and are at high-risk for hospital readmissions. Moreover, the sterile trauma from long-segment spinal surgeries is a tremendous systemic inflammatory stimulus that yields downstream sequelae such as hyperglycemia, elevated inflammatory markers (e.g. cytokines), signs of microvascular ischemia, and other stress-related outcomes. Attempts to control this inflammation and reduce the adverse effects of these surgeries are lacking, particularly with respect to non-pharmacologic options.
Vagal nerve stimulation (VNS) is a promising emerging modality by which the body's systemic inflammatory response may be attenuated. Importantly, VNS may be successfully applied via noninvasive auricular stimulation. This technique has been trialed as non-pharmacologic pain control adjunct after multiple types of surgeries or painful medical events, but none as traumatic as long-segment spinal fusion. It also has been shown to yield substantial anti-inflammatory effects in numerous animal models. Furthermore, auricular VNS has been extensively studied at Washington University School of Medicine in multiple neurological conditions, including aneurysmal subarachnoid hemorrhage, acute ischemic stroke, and intraparenchymal hemorrhage. The use of noninvasive VNS devices has been shown to be an intervention that is safely administered and does not cause undue distress to patients. Given these promising aspects of VNS, Washington University's particular interest in this treatment modality, and the unmet postoperative care needs for long-segment spinal fusion patients, the investigators propose prospectively studying the effects of auricular VNS in a population of patients at Barnes-Jewish Hospital who have undergone long-segment fusion surgeries. The investigators hypothesize that perioperative VNS will mitigate the systemic inflammatory reaction in these patients as demonstrated by reduced inflammatory markers (both direct and indirect) and improved inflammatory-mediated clinical outcomes.
This study will be a randomized controlled trial assessing differences between accepted perioperative care plus auricular VNS (the intervention) as compared to accepted perioperative care plus a sham stimulus. The VNS device will be a noninvasive stimulator applied to the left ear to stimulate the auricular branch of the vagus nerve. All patients will be fitted with the device, and the sham stimulus will not receive the required therapeutic stimulation through the device. Patients will receive stimulation twice on the day of surgery followed by twice daily during the duration of their postoperative hospital admission. Relevant inflammatory cytokines, laboratory tests, pain scores, clinical outcomes, and imaging studies will be obtained for each patient. Post-hospital disposition, delayed adverse outcomes, and hospital readmissions will also be tracked after discharge.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Participants will be assigned to either the vagal nerve stimulation arm or the sham stimulation arm.
| Arm | Type | Receives |
|---|---|---|
| Auricular vagal nerve stimulation | Experimental | Device: Auricular vagus nerve stimulationParticipants will receive vagal nerve stimulation twice on the day of surgery (once preoperatively) and twice daily postoperatively for duration of hospitalization. All patients will be fitted with the device via adhesive contacts to the left ear. Stimulation will occur for 20 minutes per session. The intervention will provide stimulation according to the following parameters: frequency 20 Hz, pulse width 250 µm, and fixed intensity of 0.5 milliampere. The amplitude of stimulation may be reduced if a patient complains of discomfort at the site of stimulation |
| Sham vagal nerve stimulation | Sham comparator | Device: Sham Auricular Vagus nerve StimulationParticipants will have an auricular vagal nerve stimulator device applied in the same manner as the experimental arm, but they will not receive the actual stimulation. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Long-segment spinal fusions (defined as constructs spanning at least L2-pelvis for thoracolumbar fusions or C2-T2 for cervical fusions)
- Ability to undergo a reliable neurologic examination and pain assessments
Key exclusion criteria (7 listed)
- Patients <18 years of age
- Shorter-segment spinal fusions than those described above
- Undergoing current active cancer therapy
- Undergoing treatment with immunosuppressive drugs
- Additional spinal surgery within past 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Auricular vagus nerve stimulationTranscutaneous auricular vagal nerve stimulation | Device | Auricular vagal nerve stimulation |
| Sham Auricular Vagus nerve StimulationTranscutaneous auricular vagal nerve stimulator applied without utilizing stimulating current. | Device | Sham vagal nerve stimulation |
Primary outcome
Inflammatory cytokine levels
Time frame: 5-10 days (depending on hospital admission length)
The levels of 4 different inflammatory cytokines will be measured: interleukin-6 (IL-6), IL-1, IL-10, and tumor necrosis factor alpha (TNF-a) (all measured in pg/ml). Blood for these tests will be drawn preoperatively, postoperatively, on postop day 3, and postop day 6 (or time of discharge).
13 secondary outcomes
Pain scores
Time frame: 5-10 days (depending on hospital admission length)
blood glucose levels
Time frame: 5-10 days (depending on hospital admission length)
Postoperative adverse events/complications
Time frame: 5-10 days (depending on hospital admission length)
Secondary markers of inflammation
Time frame: 5-10 days (depending on hospital admission length)
Post-hospitalization disposition
Time frame: 5-10 days (depending on hospital admission length)
Heart rate
Time frame: Time Frame: 5-10 days (depending on hospital admission length)
Opioid usage
Time frame: 5-10 days (depending on hospital admission length)
Insulin requirements
Time frame: 5-10 days (depending on hospital admission length)
Erythrocyte sedimentation rate (ESR)
Time frame: 5-10 days (depending on hospital admission length)
D-dimer levels
Time frame: 5-10 days (depending on hospital admission length)]
Hospital admission length
Time frame: 5-10 days (depending on hospital admission length)
Blood pressure
Time frame: 5-10 days (depending on hospital admission length)]
Readmission rates
Time frame: 60 days postoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Spinal Fusion
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Not yet recruiting
Kore Fiber PLF Study
Degenerative Lumbar Spine Diseases, Lumbar Degenerative Disc Disease
Active, not recruiting
SLIP II Registry: Spinal Laminectomy Versus Instrumented Pedicle Screw Fusion
Lumbar Spondylolisthesis, Grade 1 Spondylolisthesis
Recruiting
MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion
Degenerative Disc Disease, Spine Fusion
Enrolling by invitation
Assessing Microbiome in Primary Anterior Cervical Fusion Patients
Cervical Stenosis, Myelopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Auricular vagus nerve stimulation in people with Spinal Fusion and Hyperglycemia, run by Alexander T. Yahanda at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alexander T Yahanda, MD, MPHS (3143690198, ayahanda@wustl.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Inflammatory cytokine levels (time frame: 5-10 days (depending on hospital admission length)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.